Christopher Sorli - Concepedia

Author

Christopher Sorli

Also Known As

C H Sorli, C Sorli, C. H. Sorli, C. Sorli, CHRISTOPHER H. SORLI, Christopher H Sorli, Christopher H. Sorli, Christopher Sorli, K Sivalingam, Sorli, Christopher

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Precision Research Institute Hanmi Pharmaceutical (South Korea)Sanofi (Canada)Sanofi (United States)Catholic University of Korea

About

Christopher Sorli is an author at Precision Research Institute specializing in medicine, diabetes, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	889
2	Diabetes	4	4	879
3	Cell Biology	2	2	125
4	Biochemistry	1	1	10
5	Cellular Therapies	1	1	115

Christopher Sorli

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial Christopher Sorli, Shin‐ichi Harashima, George Tsoukas, The Lancet Diabetes & Endocrinology Diabetes ManagementSustain 1DiabetesType 2Clinical Trials	2017	648
Basal expression of cyclooxygenase-2 and nuclear factor–interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet Christopher Sorli, Huijian Zhang, Michael B. Armstrong, Proceedings of the National Academy of Sciences	1998	140
Pilot Clinical Study of an Endoscopic, Removable Duodenal-Jejunal Bypass Liner for the Treatment of Type 2 Diabetes Leonardo Rodríguez, Eliana Reyes, Pilar Fagalde, Diabetes Technology & Therapeutics	2009	131
NOD mice have a generalized defect in their response to transplantation tolerance induction. Thomas G. Markees, David Serreze, Nancy E. Phillips, Diabetes Cell TherapyImmune ToleranceTransplantation MedicineImmunologyPancreas Transplantation	1999	115
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial Erin A. Bohula, Benjamin M. Scirica, Silvio E. Inzucchi, The Lancet ObesityMetabolic SyndromeCamellia-timi 61Diabetes ManagementDiabetes	2018	94
A Pilot Study of the Duodenal-Jejunal Bypass Liner in Low Body Mass Index Type 2 Diabetes Ricardo V. Cohen, Manoel Galvão Neto, José Luis Correa, The Journal of Clinical Endocrinology & Metabolism	2013	57
Role of proximal gut exclusion from food on glucose homeostasis in patients with Type 2 diabetes Ricardo V. Cohen, Carel W. le Roux, Dimitris Papamargaritis, Diabetic Medicine	2013	47
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study Richard E. Pratley, Jahoon Kang, Michael Trautmann, Diabetes Obesity and Metabolism	2019	44
Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study Stefano Del Prato, Jahoon Kang, Michael Trautmann, Diabetes Obesity and Metabolism	2020	38
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide Julio Rosenstock, Christopher Sorli, Michael Trautmann, Diabetes Care	2019	35

Page 1